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Over a relatively short period,cystic fibrosis (CF) has gone from a disease of dying children to one 
where survival well into adulthood is expected. It was recently reported that by 2025, the adult CF 
population in Western Europe would increase by 75% (1). Although the reasons for improved 
survival are complex, one contributor is the aggressive use of antibioticsincluding 
aminoglycosides.However, aminoglycosides have well-recognised adverse effects, particularly 
nephrotoxicity and ototoxicity. Clear relationships between these effects and aminoglycoside 
concentrations or exposure have yet to be defined.  
 
Acute kidney injury has been associated with longer courses of aminoglycoside therapyand is often 
reversible.  The impact on renal function of cumulative exposure from the multiple coursesof 
aminoglycosides commonly encountered by patients with CF is less clear.Al-Aloul et al (2)identified a 
negative linear relationship between the lifetime number of aminoglycoside courses and creatinine 
clearance, particularly in the presence of IV colistin, whereas Pedersen et al (3) found no correlation 
between cumulative tobramycin dose and glomerular filtration rate, and Alghanem et al (4) found 
no change in aminoglycoside clearance over time in adultswho had received between 10 and28 
courses.Variations in dosing and monitoring approaches, frequency and duration of individual 
courses and the presence of other risk factors confound the interpretation of the findings in these 
studies. It is also not clear whether multiple courses over a short time are more risky than the same 
number over several years. 
Studies have also failed to clearly identify the level of exposure that would lead to an unacceptable 
risk of ototoxicity.   Although hearing loss is more likely in patients who have received multiple 
courses of aminoglycoside therapy, the nature of this relationship is likely to be non-linear and 
linked to other factors, such as age and lung function (5).  The precise prevalence of ototoxicity is 
unclear as data are limited, but in one series (n=153) of adult CF patients, 50.8% had some evidence 
of auditory impairment (6). We need more studies, not only to accurately quantify the problem, but 
also to identify the potential contribution of other potentially ototoxic drugs (e.g. azithromycin), 
other routes of administration (e.g. nebulised tobramycin) and to allow us to compare tobramycin, 
non-aminoglycoside IV antibiotics (e.g. colistin) and amikacin, since the risks of ototoxicity and 
nephrotoxicity may not be the same for these antibiotics.  This is particularly important with the 
increasing use of amikacin to treat infections such as non-tuberculous mycobacteria.   
 
So, what is the answer? Can we reduce the need for aggressive IV antibiotic policies in the era of 
multiple inhaled antibiotics - especially if the promise of better lung health with the early use of 
gene/protein modifying therapies is realised? When IV aminoglycosides cannot be avoided, 
alternative dosing regimens and adjunctive therapies mĂǇďĞƵƐĞĨƵů ?dŚĞ ?dKW/ ?ƐƚƵĚǇƉƌŽǀĞĚƚŚĂƚ
once daily dosing has equal efficacy to thrice daily dosing, with less nephrotoxicity for children (7), 
while the prospective, randomised study by Prayleet al  in the current edition of the Journal 
challenges current practices regarding the timing of once-daily dosing (8). Despite no detectable 
difference in tobramycin clearance between morning and evening administration, the finding of a 
raised KIM-1 (a biomarker of nephrotoxicity) suggests that aminoglycoside doses may be bettergiven 
in the morning rather than at night. Perhaps more importantly, it encourages us to consider novel 
ways of administering old drugs to improve long term safety.  
Another approach may be to use adjunctive therapy to mitigate the risks. In the current edition of 
the Journal, Fox et alinvestigate the co-administration of high doses of D-methionine and tobramycin 
to guinea pigs and found that methionine reduced tobramycin-induced ototoxicity without 
interfering with the anti-ŵŝĐƌŽďŝĂůĞĨĨĞĐƚ ? ? ? ?WƌĞǀŝŽƵƐƐƚƵĚŝĞƐǁŝƚŚƉŽƚĞŶƚŝĂůůǇ ?ƉƌŽƚĞĐƚŝǀĞ ?ƚŚĞƌĂƉŝĞƐ ?
such as N-acetyl cysteine and aspirin, have highlighted the challenges of translating this approach 
into clinical practice;nevertheless,the principle holds promise.  
 
A key issue for the future is the need for a more standardised approach to the monitoring of adverse 
effects, particularly ototoxicity. Collaboration with colleagues in audiological and renal medicine will 
be important to develop effective guidelines.There is increasing evidence to support the 
introduction of routine audiometric testing, both as a safety measure and to support further 
research into the relative importance of drug exposure, genetic susceptibility and ageing on the 
development of ototoxicity. The methods used to assess hearing and vestibular function are also 
important since standard pure tone audiometry may be unable to detect the minor changes in 
hearing identified by more sensitive techniques (5).   
 
Unless there is a dramatic shift in antibiotic drug discovery, we will rely on aminoglycosides for the 
ĨŽƌĞƐĞĞĂďůĞĨƵƚƵƌĞ ?hŶĚŽƵďƚĞĚůǇƚŚĞǇŚĂǀĞďĞĞŶĂ ?ĨƌŝĞŶĚ ?ŽĨƚŚĞCF community for a long time, 
ŚŽǁĞǀĞƌ ?ƚŚŝƐƌĞůĂƚŝŽŶƐŚŝƉŝƐŶŽǁƵŶĚĞƌƐĐƌƵƚŝŶǇ ? ?ůĞƐƐĂ ?ĨŽĞ ? ? ?ŵŽƌĞĂŵĂƚƵƌĞĚƌĞůĂƚŝŽŶƐŚŝƉǁŚŝĐŚ
needs re-adjustments to ensure we optimise their use to enhance both the quantity and quality of 
ŽƵƌƉĂƚŝĞŶƚƐ ?ůŝǀĞƐĂƐƚŚĞǇŐƌow older.    
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